Platelet-Rich Plasma vs. Novel Cross-linked Hyaluronic Acid Injection for Early Knee Osteoarthritis .
Comparing the Efficacy of Intra-Articular Single Platelet-Rich Plasma(PRP) versus Novel Crosslinked Hyaluronic Acid for Early-Stage Knee Osteoarthritis: A Prospective, Double-Blind, Randomized Controlled Trial
Medicina (Kaunas). 2022 Aug 1;58(8): 1028.116 patients with early-stage knee osteoarthritis were randomized to receive a single intra-articular injection of a novel cross-linked hyaluronic acid (HA; n=58) or platelet-rich plasma (PRP; n=58). The outcome of interest was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and associated sub-scores, measured at 1, 3 and 6 months follow-up. Results revealed similar scores between groups in all outcomes, at all time-points.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
